Replimune Group (NASDAQ:REPL) Shares Up 6.4% – Here’s Why

by · The Cerbat Gem

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) shot up 6.4% on Wednesday . The stock traded as high as $8.76 and last traded at $8.94. 291,629 shares changed hands during mid-day trading, a decline of 66% from the average session volume of 858,083 shares. The stock had previously closed at $8.40.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on REPL shares. BMO Capital Markets increased their price objective on Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd. HC Wainwright upped their price target on Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Replimune Group has an average rating of “Buy” and a consensus target price of $19.43.

Read Our Latest Report on REPL

Replimune Group Trading Down 5.4 %

The stock has a market cap of $574.53 million, a PE ratio of -2.43 and a beta of 1.26. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. The firm has a fifty day simple moving average of $12.39 and a two-hundred day simple moving average of $12.09.

Replimune Group (NASDAQ:REPL – Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09). As a group, equities analysts expect that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Institutional Trading of Replimune Group

Institutional investors and hedge funds have recently made changes to their positions in the stock. Sterling Capital Management LLC grew its position in Replimune Group by 364.5% in the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock worth $26,000 after acquiring an additional 1,655 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in Replimune Group by 696.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company’s stock worth $82,000 after purchasing an additional 5,922 shares during the last quarter. Aster Capital Management DIFC Ltd boosted its holdings in shares of Replimune Group by 8,798.9% in the 4th quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company’s stock worth $100,000 after purchasing an additional 8,183 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Replimune Group in the 4th quarter worth about $117,000. Finally, Quantinno Capital Management LP bought a new position in shares of Replimune Group during the 4th quarter valued at about $127,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

About Replimune Group

(Get Free Report)

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

Featured Articles